Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancer

Japanese Journal of Clinical Oncology

Volumn 42, Issue 8, 2012, Pages 663-669

  Kurata, Takayasu ^a   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bisphosphonate; Bone metastasis; Denosumab; Skeletal related event

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; DOCETAXEL; FC RECEPTOR; I KAPPA B; IMMUNOGLOBULIN HEAVY CHAIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; OSTEOPROTEGERIN FC; PAMIDRONIC ACID; PLACEBO; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADVANCED CANCER; BONE METASTASIS; BREAST CANCER; CANCER PATIENT; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY DISEASE; MULTIPLE MYELOMA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT;

ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS; RANK LIGAND;

EID: 84865084453     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys088     Document Type: Review

References (28)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80(8 Suppl):1588.
2. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84.
3. Koizumi M, Yoshimoto M, Kasumi F, Iwase T, Ogata E. Post-operative breast cancer patients diagnosed with skeletal metastasis without bone pain had fewer skeletal-related events and deaths than those with bone pain. BMC Cancer 2010;10:423.
4. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655.
5. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377.
6. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150.
7. Saad F, Gleason DM, Murray R, et al. A randomized, placebocontrolled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458.
8. Hayashi S, Hanamura T. Encounter of cancer cells with bone. Development of bone metastasis-specific targeting therapy. Clin Calcium 2011;21:389.
9. Bouganim N, Clemons MJ. Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block? Future Oncol 2011;7:381.
10. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213s.
11. Chayahara N, Minami H. Treatment of bone metastasis with anti-RANKL antibody. Clin Calcium 2011;21:1217.
12. Ogata A, Kohno N. Current and future treatment of bone metastases in breast cancer. Jpn J Breast Cancer 2009;24:329.
13. Twelve-month non-clinical safety study using monkeys. Approved assessment material to Pharmaceutical and Medical Devices Agency, Japan (http://www.info.pmda.go.jp/shinyaku/P201200013/index.html).
14. Canon JR, Roudier M, Bryant R, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008;25:119.
15. Miller RE, Roudier M, Jones J, et al. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 2008;7:2160.
16. Pharmacology of RANKL inhibition in H1299 non-small-cell lung cancer xenogeneic transplant mouse model. Approved assessment material to Pharmaceutical and Medical Devices Agency, Japan (http://www.info.pmda.go.jp/shinyaku/P201200013/index.html).
17. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431.
18. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132.
19. Steger GG, Bartsch R. Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion. Ther Adv Med Oncol 2011;3:233.
20. Smith HS. Painful osseous metastases. Pain Physician 2011;14:E373.
21. Cleeland CS, Patrick DL, Fallowfield L, et al. Comparing the effects of denosumab and zoledronic acid on pain interference with daily functioning in a randomized phase 3 trial of patients with breast cancer and bone metastases. The 33rd Annual San Antonio Breast Cancer Symposium (SABCS) 2010;P1-13-01. http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_745.
22. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011;29:1221.
23. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745.
24. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813.
25. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221.
26. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125.
27. Analysource. Analysource Online. http://www.analysource.com (March 2012, date last accessed).
28. Xie J, Namjoshi M, Wu EQ, et al. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm 2011;17:621.